Edwards Lifesciences (EW) FY2024 10-K Annual Report
Edwards Lifesciences (EW) 10-K annual report for fiscal year 2024, filed with SEC EDGAR on Feb 28, 2025. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
Edwards Lifesciences FY2024 10-K Analysis
Business Overview
- • Core business model: Development, manufacturing, and marketing of structural heart therapies and medical technologies globally
- • New emphasis on divestiture of Critical Care product group completed Sept 2024 to refine portfolio focus
- • Strategic shift towards managing acquisitions integration risks and divesting underperforming or non-core assets
- • Operating globally with risks from currency fluctuations; no specific employee or R&D spend changes disclosed
- • Noteworthy operational complexity and financial risk from transitional arrangements after Critical Care divestiture
Management Discussion & Analysis
- • Revenue $5.44B, up $429.5M (8.6%) YoY in 2024, driven by TAVR and TMTT growth
- • Gross profit margin declined due to foreign currency impact; exact margin % figures not disclosed
- • Best segment: United States $3.21B (+$258.1M, +8.8%); worst segment: Japan $340M (-$11M, -3.1%)
- • Sold Critical Care for $4.2B; invested 19% of net sales in R&D; dividend and buyback data not provided
- • Management focuses on innovation, clinical trials, and structural heart disease treatment; expects growth via new product launches and acquisitions
Risk Factors
- • No specific, timely regulatory or legal risk identified in the text
- • No geopolitical or macroeconomic threat with concrete exposure details mentioned
- • Cybersecurity risk managed by Chief Information Security Officer with regular Board updates on detection and response capabilities
- • No direct competitor or market disruption risk detailed in the provided section
- • Enterprise-wide risk management overseen by senior leadership with dedicated councils but no financial or structural risk specifics disclosed
Edwards Lifesciences FY2024 Key Financial MetricsXBRL
Revenue
$5.4B
▼ -9.4% YoY
Net Income
$4.2B
▲ +197.7% YoY
Gross Margin
79.5%
▲ +243bp YoY
Operating Margin
25.3%
▼ -20bp YoY
Net Margin
76.7%
▲ +5339bp YoY
ROE
41.8%
▲ +2066bp YoY
Total Assets
$13.1B
▲ +39.4% YoY
EPS (Diluted)
$6.97
▲ +203.0% YoY
Operating Cash Flow
$542M
▼ -39.5% YoY
Source: XBRL data from Edwards Lifesciences FY2024 10-K filing on SEC EDGAR. All figures in USD.
Other Edwards Lifesciences Annual Reports
Get deeper insights on Edwards Lifesciences
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.